Co-founder/ CEO
Delineate Inc., United States
Emily Nieves received her bachelor's degree in Biological Engineering from the University of Georgia, where she spent significant time working in the Hallow cardiorenal lab. She has previously worked on Quantitative Systems Pharmacology and machine learning models for applications spanning the cardiorenal system, metabolism, and cell therapies for companies like Pfizer and AstraZeneca. She is also a PhD candidate in biological engineering at MIT, where she studies hybrid AI and scientific machine learning algorithms. Emily is currently co-founder and CEO of Delineate, a seed-stage startup focused on applying large language models and other AI techniques to accelerate MIDD workflows.
Disclosure information not submitted.
Envisioning the Role of GenAI in Modern Pharmacometric Workflows
Monday, October 20, 2025
2:00 PM - 3:30 PM MDT
Leveraging GenAI for the creation of fit-for-purpose datasets from literature
Monday, October 20, 2025
2:20 PM - 2:40 PM MDT
Panel - Envisioning the Role of GenAI in Modern Pharmacometric Workflows
Monday, October 20, 2025
3:00 PM - 3:30 PM MDT